Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 1994, and the nine-month period ended September 30, 1994, for Eastman Kodak Company. The company is in the midst of a significant strategic restructuring, divesting its non-imaging health businesses (Sterling Winthrop Inc., L&F Products, and Clinical Diagnostics Division) to focus on its core imaging operations. The financial statements reflect these businesses as discontinued operations.
Key Financial Metrics
| Metric (in millions) | Q3 1994 | Q3 1993 | 9 Months 1994 | 9 Months 1993 |
|---|---|---|---|---|
| Total Revenues | $3,531 | $3,187 | $9,779 | $9,337 |
| Net Earnings (Loss) | $193 | $(68) | $539 | $(1,716) |
| Earnings from Continuing Ops | $193 | $(74) | $633 | $424 |
| Operating Cash Flow (9 Mo) | $850 | $1,224 | $850 | $1,224 |
| Cash & Equivalents (End Period) | $585 | $1,635 (Dec 31, 1993) | $585 | $1,635 (Dec 31, 1993) |
| Short-Term Borrowings | $2,460 | $611 (Dec 31, 1993) | $2,460 | $611 (Dec 31, 1993) |
| Long-Term Borrowings | $4,667 | $6,727 (Dec 31, 1993) | $4,667 | $6,727 (Dec 31, 1993) |
| Working Capital | $407 | $2,804 (Dec 31, 1993) | $407 | $2,804 (Dec 31, 1993) |
Material Changes vs. Prior Period
- Revenue Growth: Sales from continuing operations increased 12% in Q3 1994 and 6% year-to-date compared to 1993. This growth was driven by volume increases and the initial consolidation of Qualex (acquired August 1994), partially offset by lower effective selling prices.
- Profitability: Earnings from continuing operations improved significantly compared to Q3 1993, which included a $495 million restructuring charge. However, on a comparable basis excluding restructuring, earnings decreased due to cost escalation, lower selling prices, and asset impairment charges.
- Discontinued Operations: The 1993 year-to-date loss of $1.7 billion was primarily due to a $2.17 billion after-tax charge for the adoption of SFAS No. 106 and 112 regarding postretirement benefits. In 1994, the health businesses are reported as discontinued operations, with a Q3 loss of $44 million deferred pending the finalization of sales.
- Liquidity: Cash and cash equivalents decreased from $1.635 billion at year-end 1993 to $585 million at September 30, 1994. This reduction was used to redeem long-term debt and unwind interest rate derivatives. Short-term borrowings increased by $1.849 billion to fund these redemptions pending proceeds from divestitures.
Guidance, Outlook, and Risks
- Divestiture Progress: Kodak has completed or announced agreements to sell its health businesses for approximately $7.86 billion in cash (Sanofi: $1.675B, SmithKline Beecham: $2.925B, Johnson & Johnson: $1.008B, Reckitt & Colman: $1.55B, Forstmann Little: $0.7B). Proceeds are expected to be used to further reduce debt.
- Debt Reduction Program: In October 1994, Kodak announced a tender offer for up to $4.8 billion of long-term debt, with $2.7 billion tendered. The company expects to incur approximately $160 million in pre-tax losses related to the tender offer and another $220 million related to unwinding interest rate derivatives, to be recognized as extraordinary charges in Q4 1994.
- Restructuring: Management indicated a focus on cost management and the possibility of a restructuring program in Q4 1994 that could materially impact results.
- Environmental: Kodak settled an EPA complaint regarding Kodak Park for a $5 million penalty and agreed to an eight-year environmental improvement program. The company is also a potentially responsible party at fewer than twenty Superfund sites, though costs are not expected to be material.
Investor Verification Checklist
- Divestiture Closing Dates: Verify the final closing dates and actual cash proceeds received for the Sterling Winthrop, L&F Products, and Clinical Diagnostics sales to confirm the timing of debt paydown.
- Q4 Extraordinary Charges: Monitor the Q4 1994 earnings release for the specific recognition of the ~$380 million in pre-tax losses related to debt tender offers and derivative unwinds.
- Restructuring Costs: Confirm if a new restructuring program is announced in Q4 and the estimated cost impact on future earnings.
- Debt Maturity Profile: Review the updated long-term debt schedule following the October tender offer to assess refinancing risks and interest expense reductions.
- Qualex Integration: Assess the financial performance of the newly consolidated Qualex subsidiary to determine if it meets revenue and margin expectations.